Pan-Birmingham Cancer Network NCAT Commissioning Exemplar Breast Cancer Surgery 4 th November 2010.

Slides:



Advertisements
Similar presentations
Transforming health care Transferable learning from Kaiser Permanente Mary Burrows.
Advertisements

Dr Cheung Chi Ying Genevieve
Best Practice Tariffs Falls and Fractures: Towards Best Practice Sam Alderson Economic Adviser – PbR Development Team.
Mammary ductal carcinoma
Shared Decision Making – a strategic framework for commissioners 2 May 2012.
Baptist Health System General Surgery Residency Program
C Commissioner Perspective How Quality Neonatal Clinical Indicators may relate to CQINs & QIPPs Ruth Moore Network Manager/Lead Nurse SSBC Newborn Network.
Influencing specialised commissioning Responding to the consultation on service specifications and clinical policies Alastair Kent OBE Director Genetic.
Increased Postoperative Complications in Bilateral Mastectomy Patients Compared to Unilateral Mastectomy: An Analysis of NSQIP Database Osman F, Saleh.
Interpreting the Commissioning for Value Packs
Cancer of Unknown Primary Dr Chris Jones Consultant Medical Oncologist North of England Cancer Network Annual Conference 20 September 2013.
Slides produced by the MBR Project Team
DCIS – Are we cutting it? Dr Alex Lemaigre With thanks to:
Which women are having a Hysterectomy and why? A plain English presentation of the methodology and findings of a database linkage study Dr Helen Stokes-Lampard.
Using Payment by Results to commission better quality clinical care Eileen Robertson Payment by Results (PbR) Development Team.
Future of Payment by Results (PbR) PCT network – 19 Feb 2007.
Commissioning products: What are they? How do they deliver better services for patients? Frances Flinter Chair, Medical Genetics CRG UKGTN Conference 22.
23 hour surgery Beth Jackson Senior Clinical Nurse Specialist Breast Unit The Royal Marsden Hospital NHS Foundation Trust.
Suspicious axillary / groin lymph node diagnostic pathway Dr P Holloway 1.
West Midlands Cancer Intelligence Unit NHSBSP Surgical QA Data for the Year of Screening 1 April 2002 to 31 March 2003 Dr Gill Lawrence and Professor Jan.
The National Mastectomy and Breast Reconstruction Audit Key findings of the Third Annual Report Slides produced by the MBR Project Team. © The National.
Breast Cancer Surgery Challenging Preconceptions Hamish Brown Consultant Breast and General Surgeon Sandwell and West Birmingham Hospitals NHS Trust
Commissioning for Value Tool Bryn Shorney Analytical Services.
RSR Books, Training, Solutions, Consultants RSR Consultants Ltd making finance work for you ©RSR Consultants Ltd Pre-operative.
Variations in Cancer Surgery Across the East Midlands and North Trent EMPHIN Forum (Apr 2010) Carolynn Gildea Trent Cancer Registry.
How are we doing? Quality in Breast Cancer Care Dr Michelle Goecke Surgical Oncology Network Update October 18, 2014.
NICE quality standard for COPD Craig Grime Technical Analyst Quality Standards NICE
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
London cancer services: Implementing the model of care London Borough of Bromley Health Scrutiny Sub-Committee meeting Tuesday, November 15, 2011.
Finance, Information and Cluster Reporting Paul Stefanoski Director of Resources Black Country Partnership Trust Kevin Gittins PbR Finance Lead South Staffordshire.
Emergency Department Profiles ACB WM Demand Management Forum 16 TH April 2012.
EVALUATION OF LYMPH NODES & PATHOLOGIC EXAMINATION FOR BREAST CASES Tonya Brandenburg, MHA, CTR Kentucky Cancer Registry.
NHS | Presentation to [XXXX Company] | [Type Date]1 Senates - the interface with SCNs and AHSNs Nigel Acheson Medical Director NHS England (South)
The Treatment of the Axilla in the North of England Cancer Network. Henry Cain ST7 North Tyneside.
Katie Ludwig FY1.   50, 285 New cases of breast cancer  11, 716 deaths  78% - 10 year survival rates  27% preventable cases  Source:
London Specialised Commissioning Group 10 th September 2009 Major Trauma Services for London Commissioning and Finance Arrangements Sean Overett Divisional.
© Nuffield Trust 24 October 2015 NHS payment reform: evolving policy and emerging evidence Chief Economist: Anita Charlesworth.
How are Auckland Surgeons Managing the Axilla? E Whineray Kelly, O Pellet, L Neave, J Harman, R Harman. Auckland Breast Cancer Study Group.
Radical Mastectomy is no longer the standard Improved adjuvant and neoadjuvant therapy Chemotherapy Endocrine therapy Radiation treatment Reconstruction.
Outcomes of the Older People’s Pilot and Benefits of Analysis Maggie Kufeldt Older People’s Joint Commissioning Lead.
Northern Lincolnshire Healthy Lives Healthy Futures Programme Stakeholder Presentation December 2013.
Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
Surgical Oncology Surgical Oncology 05/13/12 – 05/19/2012 David Williams Andy Young Ashley Limkemann Yula Dzhashiashvili.
NECN Colorectal NSSG Audit of Waiting Times for Lower GI Cancer Patients in NECN April 2010 – March 2011.
Radiotherapy Protocols Bristol protocol version 12.
Community Health Services Review NHS LCR Trust Board Approvals following the Review of Public Consultation Findings Rachel Seagrave Associate Director.
Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and.
HRG4: Impact on Arrhythmia Care Donna Elliott-Rotgans Cardiology Service Manager UCLH / The Heart Hospital.
Two-week wait referrals for malignant melanoma: A clinical audit carried out across four UK Cancer Networks South West Cancer Intelligence Service
Integrated CQUIN 2013/2014 Suggested Impact and Measures.
What data are collected? How, and who by? Karen Graham and Barry Plewa.
Diseases of Childhood Expert Working Group 1 st March 2012.
Creating incentives for better quality: Lessons from the English NHS Jennifer Field, Associate Director National Institute for Health and Clinical Excellence.
Dr Karl Davis Consultant Geriatrician. Public Health Wales All the frameworks highlighted the following six areas as key priorities (although there is.
NIHR Southampton Biomedical Research Centre The Southampton Biomedical Research Centre is funded by the National Institute for Health Research (NIHR) and.
Developing the GP Cancer Lead Community Dr P Sawyer Herts Valleys Macmillan Cancer Lead.
Vascular Surgery in Thames Valley Dr Will Orr Clinical Lead CVD Thames Valley NHS England 1.
WALES BREAST CANCER CLINICAL AUDIT (WBCCA) MDT DATA FOR PATIENTS DIAGNOSED in 2009, 2010 and 2011 Llandough Hospital (Cardiff and Vale UHB) MDT.
Skin Cancer and Rehabilitation Report to Skin NSSG Sally Donaghey Macmillan AHP Lead, Ang CN
Figure 1: a 32-year-old woman presented with RT breast mass, MRI showed false positive diagnosis of cancer. Dynamic contrast enhanced MRI, axial subtraction.
Commissioning for Value Focus Pack
Induction toolkit 1. introduction Welcome the group.
CASE PRESENTATION BREAST CANCER.
A Model for Breast Services in North Wales
Ductal Carcinoma (Breast Cancer)
From: Pain in 1,000 Women Treated for Breast Cancer:A Prospective Study of Pain Sensitivity and Postoperative Pain Anesthes. 2013;119(6): doi: /ALN
But how to treat those with positive SLNB? Results and Discussion
A.M. Yiacoumettis  British Journal of Plastic Surgery 
C11 Breast cancer Treatments
Presentation transcript:

Pan-Birmingham Cancer Network NCAT Commissioning Exemplar Breast Cancer Surgery 4 th November 2010

Approach Initial scoping was cross-referenced to established guidelines (NICE, NSSG, Map of Medicine) Taken the PbR datasets that are already readily available to NHS Commissioners Analysed and tested outputs with clinicians in the know Refined the data and information and retested with clinicians – Key Issues emerged Production of a Commissioner’s Guidance Note Aim is to inform the discussions between commissioners and hospital providers

Project Phases Phase 1 - Project Scoping (Established guidelines and listening to clinicians) Phase 2 – Data Crunch 1 & Clinical Networking to Identify the Issues Phase 3 – Data Crunch 2 & Addressing the Issues Phase 4 – Expanding the Scope – The Wider Clinical Pathway Phase 5 – Bringing it all Together

ICD-10 Diagnosis Codes C50 – Breast Neoplasms D05 – Ductal Carcinoma in Situ (DCIS) 2008/09 Dataset Apr 08Apr /10 Dataset Apr 10 Dec 09 9 mths Mastectomy / BCS casesFurther Ops in next12 mths The PbR Data-Set 849 ~ £2m214 ~ £430k An extended dataset for the 21-month period April 2008 to December 2009 was used to identify 849 patients who had either a mastectomy or breast conserving surgery in the 9-month period April to December It was then possible to undertake a detailed analysis of the 214 follow-up operations needed by the cohort during the course of the following year.

Key Issues that Emerged Ratio of Mastectomies.v. BCS Rate of Sentinal Node Biopsy Conversion of SNB to Full Axillary Clearance The need for further surgery after BCS Cases planned and achieved as 23hr/daycase Reconstruction Consultant Caseload

Presenting a Data Summary Dashboard Created

A Separate Dashboard for each of the main pan-Birmingham Hospitals

Proportion of patients requiring only a single operation Conserving the Axillary Lymph Node Tissue Ratio of Mastectomies to Breast Conserving Surgery The Need for Additional SurgerySimultaneous Reconstruction Payment by Results Tariff Details ££ Conserving Breast Tissue Number of Initial BCS & Mastectomies

Delving Deeper into the Data to Address the Key Issues

Can anything be done to reduce the number of second operations

Sentinel Node Biopsy Breast Conserving Surgery + Sentinel Node Biopsy HRG JA07 a,b or c PbR £2,053 to £2,764 Axillary Clearance HRG JA06 PbR £2,760 Histology Breast Conserving Surgery + Sentinel Node Biopsy Histology in Theatre and proceed to Axillary Clearance if needed HRG JA06 / JA07 a,b or c PbR £2,053 to £2,764 £4,813 to £5,524£2,053 to 2,764 List planning / Theatre Time / Equipment £400/case extra

Sentinel Node Biopsy Total Ops Apr'08 to Dec'08 Partial Mastectomy Axilla NILSampleSNBClearance Ops% % % % 124HEFT2520%22%6653%3125% 160 SWBH 3824%43% 98 67%2013% 109UHB2725%11%5447%2725% 70Walsall1014%4361%1521%23% 23Other Hospitals417%4 1048%522% 486All Hospitals10421%5411%24349%8517% £ PbRExpenditure Axilla NILSampleSNBClearance £ total £ average£ total £ average£ total £ average£ total £ average £223,772HEFT£42,611£1,686£3,512£1,756 £122,00 5 £1,848£55,644£1,798 £291,416SWBH£65,870£1,733£6,794£1,699 £179,94 0£1,836£38,812£1,941 £201,971UHB£50,522£1,829£1,907 £100,77 1£1,866£48,771£1,824 £123,708Walsall£15,034£1,503£78,377£1,823£26,634£1,776£3,663£1,857 £43,665Other Hospitals£7,024£1,781£9,999£2,500£17,862£1,489£8,780£1,463 £884,532All Hospitals £181,06 1£1,725 £100,58 9£1,863 £447,21 2£1,825 £155,67 0£1,818 Using the Data to Quantify the Key Issues

SNB to Full Ax Clearance Total Ax Clearances % of snb SNB converting to Axillary Clearance at Time of Further Mastectomy NonePartialFull Ops% % % 46%HEFT 250% % SWBH 9 53% 3 18% 5 29% 611%UHB350%3 17%Walsall 1100% 330%Other Hospitals133% 267% 3113%All Hospitals1342%826%1032% £Expenditure at Time of Further Mastectomy NonePartialFull £ total £ average£ total £ average£ total £ average £10,330HEFT £4,456£2,228£5,874£2,937 £42,920SWBH£22,364£2,485£7,081£2,360£13,473£2,695 £15,037UHB£7,647£2,549£7,390£2,463 £2,937Walsall £2,937 £9,903Other Hospitals£2,549 £7,354£3,677 £81,127All Hospitals£32,560£2,505£18,927£2,366£29,638£2,964

Sentinel Node Biopsy Breast Conserving Surgery + Sentinel Node Biopsy HRG JA07 a, b or c PbR £2,053 to £2,764 Axillary Clearance HRG JA06 PbR £2,760 Histology Breast Conserving Surgery + Sentinel Node Biopsy Histology in Theatre and proceed to Axillary Clearance if needed HRG JA06 PbR £2,760 £4,813 to £5,524£2,760 List plannning £400/case extra City Hosp x £400 = £39,200 City Hosp x £2,760 = £46,

Sentinel Node Biopsy Breast Conserving Surgery + Sentinel Node Biopsy HRG JA07 a, b or c PbR £2,053 to £2,764 Axillary Clearance HRG JA06 PbR £2,760 Histology Breast Conserving Surgery + Sentinel Node Biopsy Histology in Theatre and proceed to Axillary Clearance if needed HRG JA06 PbR £2,760 £4,813 to £5,524£2,760 List plannning £400/case extra City Hosp 98 x £400 = £39,200 City Hosp 17 x £2,760 = £46,920 Invest £39,200 to Save £46,920 Only 1 operation for patient instead of 2 Should we be petitioning for Best Practice Tariff ? CQUIN ? Commissioners and Providers now have something to talk about that is evidence based Leverage for Better Care